Comparative Price Analysis of Biological Products for Treatment of Rheumatoid Arthritis
Open Access
- 20 September 2018
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 9, 1070
- https://doi.org/10.3389/fphar.2018.01070
Abstract
Biological products for treatment of rheumatoid arthritis usually are cost effective for healthcare systems in Europe, but they are huge financial burden due to the high number of patients and the significant budget impact. The expected saving from introduction on the market of biosimilars are significant and are linked to better access and affordability. The aim of this study was to conduct comparative price analysis of biological products for rheumatoid arthritis therapy among seventeen EU countries. The point of view is that of the Bulgarian pricing and reimbursement system and the chosen countries are those from external reference basket for prices comparison at manufacturing level. All authorized biological products by EMA with therapeutic indication rheumatoid arthritis were selected. The access for treatment is evaluated as the availability of the product on the market and the prices level. We assessed the availability of all trade names in the price lists of the observed countries. The prices data was obtained from the official web pages of the responsible institutions up to date December 2017. The results show that four out of all six INNs have authorized biosimilars in EMA. Despite its earlier authorization biosimilar adalimumab is not present in any of the price lists of countries. From all eighteen countries only in Lithuania and Estonia there were no published prices of any of the selected medicinal products. Countries with higher number of biosimilar prices are Spain and France. Differences in manufacturers’ prices of reference biological products in selected countries in comparison with the lowest manufacturer price are higher with 22 to 69% while the retail prices between 62 and 95%. Differences are mostly notable for rituximab, and less notable for tocilizumab. Manufacturers’ and retail prices of biosimilar products were established only for three INNs (etanercept, rituximab, and infliximab). Manufacturers’ prices differ between 26 and 75%, while retail prices differ between 40 and 92% for biosimilars. Comparison of the differences between manufacturer prices of reference biological product and biosimilars shows 36% difference for etanercept, 39% for rituximab, and 31% for infliximab, while at retail level the differences are 11, 86, and 143%, respectively. The limitation of the study is that the prices are the official ones without discounts due to confidentiality and the real prices may be lower. The second limitation is that the methodology for pricing differs in the countries and this could also influence the prices on both levels (manufacturer and retail). Introduction of biosimilars on the national markets led to significant decrease in reimbursed prices paid by public funds and thus might benefit the patients’ access to biological therapy. The decrease of prices after biosimilars entrance on the market is not as notable as for commodity generics.This publication has 35 references indexed in Scilit:
- Biosimilars in the European marketGenerics and Biosimilars Initiative Journal, 2013
- A European perspective on the market accessibility of biosimilarsBiosimilars, 2012
- Saving money in the European healthcare systems with biosimilarsGenerics and Biosimilars Initiative Journal, 2012
- Do rheumatoid arthritis patients have equal access to treatment with new medicines? Tumour necrosis factor-alpha inhibitors use in four European countriesHealth Policy, 2012
- American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical TrialsAnnals Of The Rheumatic Diseases, 2011
- Access to biologic treatment for rheumatoid arthritis in Central and Eastern European (CEE) countriesMedical Science Monitor, 2011
- Cost‐effectiveness of biologic response modifiers compared to disease‐modifying antirheumatic drugs for rheumatoid arthritis: A systematic reviewArthritis Care & Research, 2010
- 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiativeAnnals Of The Rheumatic Diseases, 2010
- International guidelines on access to biologic therapy: why the differences and which is best?Nature Clinical Practice Rheumatology, 2008
- The burden of rheumatoid arthritis and access to treatment: health burden and costsThe European Journal of Health Economics, 2007